BioCentury | Oct 27, 2020
Product Development

Mirati impresses with KRAS inhibitor response rates, potential biomarker

...market close on Monday, Mirati proposed a $700 million public offering.TARGETSCDK4 – Cyclin-dependent kinase 4CDK6 – Cyclin-dependent kinase...
BioCentury | Oct 24, 2020
Translation in Brief

UNC Chapel Hill Angelman gene therapy rescues motor function; plus data backing planned Pacylex, Kronos clinical trials and more

AAV gene editing therapy for Angelman syndromeUniversity of North Carolina at Chapel Hill scientists have created a CRISPR gene therapy for Angelman syndrome that ameliorated motor function deficits in a mouse model of the maternally...
BioCentury | Oct 21, 2020
Deals

With roots in Medivation, Nuvation finds quick route to listing via year’s largest SPAC deal

The team that backed Medivation is returning to the U.S. public markets as Nuvation with a fresh injection of $644 million through a reverse merger with EcoR1’s SPAC Panacea and a PIPE backed by 16...
BioCentury | Sep 30, 2020
Product Development

Ovid looks to broad path forward for rare epilepsy program

Three years after striking a deal with Takeda to take the lead on developing the Japanese pharma’s soticlestat, Ovid is considering multiple paths to market for the therapy in rare epileptic encephalopathies.  On Wednesday, Ovid...
BioCentury | Sep 15, 2020
Deals

Buoyed by Phase III data, Marinus aims for first NDA in a rare seizure disorder

A Phase III readout that boosted Marinus’ value on Tuesday is the first in a series of upcoming milestones that could lead to the company carving out a commercial niche in rare seizure disorders. Trial...
BioCentury | Aug 28, 2020
Emerging Company Profile

Concarlo: targeting proliferation and resistance in one go

...cyclin dependent kinase 6p27 (Kip1; CDKN1B) – cyclin-dependent kinase...
...inhibitor 1BPTK6 – protein tyrosine kinase 6 Virginia Li Cyclin-dependent kinase...
BioCentury | Aug 25, 2020
Finance

$155M Perceptive-led note deal enables Kronos to fund newly acquired Gilead asset’s pivotal trial

After acquiring a Phase III-ready asset from Gilead last month, Kronos raised $155 million on Monday to fund the cancer therapy’s registrational trial, slated for 2021. The funding will also enable Kronos, led by Gilead...
BioCentury | Aug 18, 2020
Product Development

Gilead, Tango expand cancer partnership; plus Roche approval, Novavax COVID-19 efficacy study and G1, Myovant and PTC applications under review

Gilead takes stake in Tango, expands 2018 dealGilead Sciences Inc. (NASDAQ:GILD) million has expanded its 2018 deal with Tango Therapeutics Inc. to cover worldwide options over seven years from five to 15 immuno-oncology targets in exchange...
BioCentury | Jul 31, 2020
Finance

Polyphor gains financial cushion ahead of Phase III readout of lone clinical program

A new equity financing should give Polyphor a little more financial breathing room as the Swiss biotech tries to broaden its pipeline and move away from an all-or-nothing Phase III coin flip in 1Q21. Polyphor...
BioCentury | Jul 25, 2020
Translation in Brief

New class of cytosine base editors; plus new U.K. vaccine manufacturing facilities, scalable surrogate assay for COVID-19; combating antibiotic resistance and

...CDK6 - Cyclin dependent kinase 6 DRD3 - Dopamine D3 receptor CDKN1B (p27, Kip1) - Cyclin-dependent kinase...
Items per page:
1 - 10 of 597